$EVAX News

Evaxion A/S 2026 Q1 - Results - Earnings Call Presentation

Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026

European Equities Traded in the US as American Depositary Receipts Rise Friday

Evaxion (EVAX) Q1 2026 Earnings Transcript

Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript

Evaxion (NASDAQ:EVAX) Beats on Operating Metrics, but Market Waits for Revenue

Evaxion announces business update and first quarter 2026 financial results

Evaxion Biotech Q1 EPS $(0.01) Beats $(0.23) Estimate

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO

HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Evaxion's Announces Its Data Demonstrating AI-Immunology Traces, Selects Therapeutically Relevant Vaccine Targets; 88% Vaccine Targets Trigger Tumor-Specific Immune Response

Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR

Evaxion concludes Annual General Meeting

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress